Filing summary
Entity note: The supplied filing is Cortexyme, Inc.’s Form 10-Q, not a filing for Quince Therapeutics, Inc. It covers the quarter ended March 31, 2019 and was signed June 12, 2019.
Business context and reporting period
Cortexyme was a clinical-stage biopharmaceutical company developing COR388, an oral investigational drug candidate targeting gingipain proteases, for Alzheimer’s disease. The company reported no revenue and continued to fund research and development through financing. Financial statements are unaudited.
Financial results and liquidity
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $4.825 million | $2.413 million; up 100% |
| General and administrative expense | $1.250 million | $0.347 million; up 260% |
| Total operating expenses | $6.075 million | $2.760 million |
| Net loss | $5.681 million | $3.377 million |
| Net loss per share | $1.61 | $1.01 |
| Net cash used in operating activities | $7.216 million | $3.177 million |
At March 31, 2019, cash and cash equivalents were $20.634 million, short-term investments $38.410 million, and long-term investments $5.416 million. Management cited $59.0 million in cash, cash equivalents and short-term investments and believed it would fund planned operations for at least 12 months. Total assets were $70.596 million; total liabilities were $4.485 million, including $0.815 million of lease liabilities. No debt balance was reported. The company had an accumulated deficit of $38.506 million. Operating margin and profitability were not meaningful given the absence of revenue and ongoing losses.
Material changes and unusual items
- R&D spending doubled, primarily due to increased COR388 clinical-trial and drug-manufacturing costs as the program advanced into Phase 2/3; lower Phase 1 trial costs partly offset the increase.
- G&A rose substantially, mainly from public-company-related legal, accounting and professional fees and higher personnel costs.
- Operating cash use increased year over year. Investment purchases and maturities generated $3.164 million of net investing cash inflow, reflecting portfolio activity rather than operating cash generation.
- On May 13, 2019, after quarter-end, Cortexyme completed an IPO of 5,073,800 shares at $17 per share, receiving approximately $78.1 million in net proceeds. Preferred shares converted into 18,161,027 common shares at closing.
- The company adopted lease accounting effective January 1, 2019, recognizing a right-of-use asset and lease liabilities. The related-party facility lease was paid for with preferred shares; the filing states the lease liability would be fully extinguished upon the IPO.
Outlook, risks and controls
The company initiated the global GAIN Phase 2/3 trial of COR388 in April 2019 and expected top-line results by the end of 2021. Management expected R&D costs to increase substantially as trials, manufacturing and other development work expanded. It stated that additional capital might be needed; inability to obtain financing could require delaying or reducing development activities. No quantified earnings or revenue guidance was provided.
The filing reported that disclosure controls and internal control over financial reporting were not effective as of March 31, 2019 because of a previously identified material weakness involving insufficient qualified accounting resources and errors in accounting analysis and records. Remediation was underway, with completion expected during 2019, but the company cautioned it could not assure timely or effective remediation. The filing reported no material legal proceedings and no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing identifies Cortexyme, Inc., not Quince Therapeutics, Inc.
- Check subsequent COR388 trial progress and whether the stated end-of-2021 results expectation was achieved.
- Verify post-IPO cash use, current liquidity and the duration of the company’s operating runway.
- Review whether management remediated the material weakness and whether later filings report effective controls.
- Assess clinical, regulatory, manufacturing and financing risks; the filing cautions that development timing, costs and outcomes remain uncertain.